trial

Evaluation of a Cognitive Adaptive E-treatment in Schizophrenia-diagnosed Adults

NCTId NCT01422902
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 150 (actual)
Sponsored by Posit Science Corporation
Primary completion 2015-03
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
150 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2012-04
Primary completion
2015-03
Eligibility
ALL · 18 Years

Interventions & indications

Drugs
Plasticity-based Cognitive TrainingNon-plasticity-based Training

Sponsors

Posit Science CorporationLead Sponsor
National Institute of Mental Health (NIMH)Collaborator

Investigators

4
Henry W. Mahncke, PhDPrincipal Investigator
Richard Keefe, PhDPrincipal Investigator
Scott Stroup, MD, MPHPrincipal Investigator
Cate StasioStudy Director

Sites

2 total
Palo Alto, United StatesSan Francisco, United States

Linked catalysts

1
Evaluation of a Cognitive Adaptive E-treatment in Schizophrenia-diagnosed Adults — primary completion2015-03

Facts & assertions

4 sourced
Enrollment
150
Phase
PHASE2
Primary Completion Date
2015-03
Status
COMPLETED
relationships
The graph out of here
drug
Plasticity-based Cognitive Training
drug
Non-plasticity-based Training
drug
lead_sponsor
Posit Science Corporation
company
collaborator
National Institute of Mental Health (NIMH)
company
indication
Schizophrenia
indication
Schizophrenia
indication
Cognition Disorders
indication
investigator
Henry W. Mahncke, PhD
person
Richard Keefe, PhD
person
Scott Stroup, MD, MPH
person
Cate Stasio
person